In light of the limited availability of clinical data on pseudoephedrine in obesity, along with its significantly unbalanced risk/benefit profile, as well as of the psychophysical susceptibility of obese patients, it appears reasonable to preclude the prescription of pseudoephedrine in obese patients of any order and degree
Is retatrutide administered daily or weekly
Friction in the right places is a feature, not a flaw
For patients who are utilizing the medication for T2DM, these processes help lead to better A1c results and blood sugar control over time
Starting January 1, 2026 , several major insurance providers, including Blue Cross Blue Shield (BCBS), Cigna, Harvard Pilgrim, and UnitedHealthcare, will implement changes to their coverage of GLP-1 medications